Detection of Alzheimer's Disease (AD)-Related Seeds for AD Diagnosis

Alzheimer's Disease Clinical Trial

Official title:

Detection of Alzheimer's Disease (AD)-Related Seeds as Biomarkers for Accurate Diagnosis of AD（AD-seeds-detector）

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04850053
• Other study ID #: AD-seeds-detector
• Status: Recruiting
• Start date: August 26, 2020
• Est. completion date: December 31, 2024

Study information

• Verified date: March 2024
• Source: Capital Medical University
• Contact: Jianping Jia, Doctor
• Phone: 8610-83199449
• Email: jiajp[@]vip.126.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study will investigate the biomarkers of Aβ and Tau seeds in plasma detected by Alzheimer's disease (AD) related seeds quantitative detector (AD-seeds-detector), and their sensitivity and specificity in diagnosing AD, compared with those from age-matched cognitively normal controls, and those with other types of dementia. To perform a high throughput analysis of the amount of Aβ and Tau seeds, the investigators have developed an AD-seeds-detector, in which a fluorescence microplate reader was combined with an oscillating mixer or water-bath-type ultrasonicator.

Description:

Aβ and Tau seeds have the potential to serve as biomarkers for AD. The AD-seeds-detector could detect small quantities of Aβ and Tau seeds by taking advantage of their ability to nucleate and enhance aggregation, enabling a very high amplification of the signal. This study examines the effectiveness of using the AD-seeds-detector as a novel technique for discriminating AD from cognitively normal control and non-AD dementia by detecting small Aβ and Tau seeds in plasma. This will be an observational study aiming at using the AD-seeds-detector to detect minute amounts of Aβ and Tau seeds in plasma as novel biomarkers with high sensitivity and specificity for the accurate diagnosis of AD. To achieve this goal, the investigators will conduct two studies using the AD-seeds-detector to detect the Aβ and Tau seeds in the plasma samples. Study one: A single-center cohort that consists of well-characterized AD patients (n=150), cognitively normal controls (n=100) and non-AD dementia patients (n=50). Study two: A multi-center cohort with well-characterized AD patients (n=400), cognitively normal controls (n=400) and non-AD dementia patients (n=400).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1500
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 55 Years to 75 Years

Eligibility

Inclusion Criteria:

• Aged 55-75. Written informed consent obtained from participant or legal guardian prior to any study-related procedures. The diagnosis of AD is made using the National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria. As for non-AD dementia, the McKeith criteria are used for DLB,the revised diagnostic criteria proposed by the International behavioral variant (bvFTD) Criteria Consortium for bvFTD,the Gorno-Tempini criteria for the semantic variant FTD or non-fluent aphasia, the Movement Disorder Society Task Force criteria for PDD, the vascular behavioral and cognitive disorders (Vas-Cog) criteria for VaD, the Armstrong's criteria for CBD, the CDC's diagnostic criteria for CJD, etc. In addition, normal cognition is supported by MMSE, CDR and other cognitive function scales.

Exclusion Criteria:

• Other medical or psychiatric illness. No one can serve as an informant. Refused to complete a cognitive test and provide biospecimen.

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease

Locations

Country	Name	City	State
China	Xuanwu Hospital of Capital Medical University	Beijing	Beijing

Sponsors (11)

Lead Sponsor	Collaborator
Capital Medical University	Beijing Geriatric Hospital, First Affiliated Hospital Xi'an Jiaotong University, Henan Provincial People's Hospital, Huashan Hospital, Kaifeng Central Hospital, Shandong Provincial Hospital, The First Affiliated Hospital of Chongqing Medical Universty, West China Hospital, Xiangya Hospital of Central South University, Zhejiang Provincial People's Hospital

Country where clinical trial is conducted

China, 

References & Publications (1)

Jia J, Li T, Yang J, Chen B, Qin W, Wei C, Song Y, Wang Q, Li Y, Jia L. Detection of plasma Abeta seeding activity by a newly developed analyzer for diagnosis of Alzheimer's disease. Alzheimers Res Ther. 2022 Feb 2;14(1):21. doi: 10.1186/s13195-022-00964-2. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The area under curve of the AD-seeds-detector for the accurate diagnosis of AD	The area under curve is used to show the ability of the AD-seeds-detector to diagnose AD. The value of area under curve is higher, then the ability of the AD-seeds-detector to diagnose AD is stronger.	two years
Secondary	The sensitivity	The sensitivity is used to show the ability of the AD-seeds-detector to diagnose AD patients, and is represented by true positive/ (true positive +false negative).	two years
Secondary	The specificity	The specificity is used to show the ability of the AD-seeds-detector to avoid false AD patients and rule out AD patients, and is represented by true negative/ (false positive + true negative).	two years
Secondary	The positive predictive value	The positive predictive value is used to show the ability of the AD-seeds-detector to correctly label AD patients who test positive, and is represented by true positive / (true positive + false positive)	two years
Secondary	The negative predictive value	The negative predictive value is used to show the ability of the AD-seeds-detector to correctly label people who test negative, and is represented by true negative / (false negative + true negative)	two years
Secondary	Cellular toxcity of Aß seeds protein	Toxcity of Aß seeds protein on cells	two years
Secondary	Morphology and structure of Aß	Comparison of Morphology and structure of beta-amyloid protein between difference groups	two years